John Greally

Director, New York Center for Rare Diseases (NYCRD)

Albert Einstein College of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Functional interpretation is essential for understanding how genetic variants contribute to complex traits. Here, we identified and characterized regulatory variants in CD4+ T cells collected from 362 donors. We integrated molecular QTL mapping from single-cell RNA-seq profiles and chromatin accessibility with predicted variant effects from a deep learning model trained on chromatin accessibility data. We identified molecular features and transcription factor binding mechanisms underlying variant sharing and mediated effects across the modalities and approaches. While predicted variant effects correlated with molQTLs, only a small fraction of empirically detected molQTLs were discovered by predictive models. MolQTLs, primarily those affecting chromatin, indicated potential molecular drivers for 33% of immune-related GWAS loci, with the deep learning approach providing insights into 4.7% of GWAS loci. These results highlight the value of multi-omic data and systematic integration of empirical and predictive approaches to interpret regulatory effects of genetic variants.

Year:

2026

Sex differences are found in brain structure and function across species, and across brain disorders in humans. A major source of brain sex differences is differential secretion of steroid hormones from the gonads across the lifespan. Specifically, ovarian hormones oestrogens and progesterone are known to dynamically change structure and function of the adult female brain, having a major impact on psychiatric risk. However, due to limited molecular studies in female rodents, very little is still known about molecular drivers of female-specific brain and behavioural plasticity. Here we show that ventral hippocampal (vHIP) overexpression of Egr1, an oestrous cycle-dependent transcription factor, induces sex-dependent changes in vHIP neuronal chromatin, gene expression, and structural plasticity, along with female-specific effects on vHIP-dependent behaviours. Importantly, Egr1 overexpression and knockdown partially mimic the vHIP chromatin state associated with the high and low-oestrogenic phase of the oestrous cycle, respectively. We demonstrate that Egr1 directs neuronal chromatin opening across the sexes, although with limited genomic overlap. Our study not only reveals a sex-dependent chromatin regulator in the brain, but also provides functional evidence that this sex-dependent gene regulation drives structural and behavioural plasticity, informing sex-based treatments for brain disorders.

Year:

2025

To understand the role of non-coding sequence variation in neurodevelopmental disorders, we studied 709,222 de novo variants (DNVs) using the genomes of 20,366 individuals. We found enrichment of DNVs at cis -regulatory elements (CREs) of all somatic cell types, attributable to the deamination of 5-methylcytosine at CG dinucleotide-dense CREs. In neurodivergent individuals with or without intellectual disability (ID), the DNVs were enriched at genes implicated in autism/ID at promoter-proximal CREs of brain cell types specifically. As the properties of the DNVs were not sufficiently distinctive to explain the phenotypic associations, we performed a multivariate category-wide association study (CWAS) that revealed enrichment of DNVs in CREs of glutamatergic neurons in individuals with ID, with a random forest analysis demonstrating an increased burden of these events in these individuals with ID. Our findings are consistent with a model of non-coding variants contributing to the oligogenic heritability of neurodevelopmental disorders.

Year:

2025

Smooth muscle cell-specific myosin heavy chain, encoded by MYH11 , is selectively expressed in smooth muscle cells ( SMC s). Pathogenic variants in MYH11 predispose to a number of disorders, including heritable thoracic aortic disease associated with patent ductus arteriosus, visceral myopathy, and megacystis-microcolon-intestinal hypoperistalsis syndrome. Rare variants of uncertain significance occur throughout the gene, including MYH11 p.Glu1892Asp, and we sought to determine if this variant causes thoracic aortic disease in mice. Genomic editing was used to generate Myh11 E1892D/E1892D mice. Wild-type ( WT ) and mutant mice underwent cardiovascular phenotyping and with transverse aortic constriction ( TAC ). Myh11 E1892D/E1892D and WT mice displayed similar growth, blood pressure, root and ascending aortic diameters, and cardiac function up to 13 months of age, along with similar contraction and relaxation on myographic testing. TAC induced hypertension similarly in Myh11 E1892D/E1892D and WT mice, but mutant mice showed augmented ascending aortic enlargement and increased elastic fragmentation on histology. Unexpectedly, male Myh11 E1892D/E1892D mice two weeks post-TAC had decreased ejection fraction, stroke volume, fractional shortening, and cardiac output compared to similarly treated male WT mice. Importantly, left ventricular mass increased significantly due to primarily posterior wall thickening, and cardiac histology confirmed cardiomyocyte hypertrophy and increased collagen deposition in the myocardium and surrounding arteries. These results further highlight the clinical heterogeneity associated with MYH11 rare variants. Given that MYH11 is selectively expressed in SMCs, these results implicate a role of vascular SMCs in the heart contributing to cardiac hypertrophy and failure with pressure overload. Author Summary In this study, we explore the impact of a specific genetic variant, MYH11 p.Glu1892Asp, on the heart and blood vessels in mice. The MYH11 gene is crucial for smooth muscle cells, which are found in the walls of blood vessels and play an important role in various vascular diseases. We created mice with this genetic variant to see if it would lead to thoracic aortic disease, a condition affecting the main artery from the heart. We found that mice with the variant were similar to normal mice in many aspects, such as growth, blood pressure, and heart function, for up to 13 months. However, when we induced high blood pressure in the mice, the mutant mice showed more significant enlargement of the aorta and damage to the elastic fibers in the aortic walls. Interestingly, male mutant mice also developed heart problems, such as reduced heart pumping ability and increased heart muscle thickness, after the high blood pressure challenge. This was accompanied by signs of heart muscle cell enlargement and increased tissue stiffness. These findings suggest that this rare MYH11 variant can contribute to a range of heart and vascular issues, particularly under conditions of pressure overload, and highlight the importance of smooth muscle cells in the development of these problems.

Year:

2024

Pediatric obesity-related asthma is characterized by non-atopic T helper 1 (Th1) inflammation and steroid resistance. CDC42 upregulation in CD4+T cells underliesTh1 inflammation but the CD4+T cell subtype(s) with CDC42 upregulation and their contribution to steroid resistance are not known. Compared to healthy-weight asthma, obesity-alone and healthy-weight controls, single-cell transcriptomics of obese asthma CD4+T cells revealed CDC42 upregulation in 3 clusters comprised of naïve and central memory T cells, which differed from the cluster enriched for Th1 responses that was comprised of effector T cells. NR3C1, coding for glucocorticoid receptor, was downregulated, while genes coding for NLRP3 inflammasome were upregulated, in clusters with CDC42 upregulation and Th1 responses. Conserved genes in these clusters correlated with pulmonary function deficits in obese asthma. These findings suggest that several distinct CD4+T cell subtypes are programmed in obese asthma for CDC42 upregulation, Th1 inflammation, and steroid resistance, and together contribute to obese asthma phenotype. Summary CD4+T cells from obese children with asthma are distinctly programmed for non-allergic immune responses, steroid resistance and inflammasome activation, that underlie the obese asthma phenotype.

Year:

2024

Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort. Supplemental Table 2. List of 80 genes with RNA sequencing coverage. Supplemental Table 3. Demographics of 400 adult ALL cases. Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients. Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients. Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients. Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort. Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients. Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments. Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment. Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.

Year:

2024

Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort. Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL. Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations. Supplemental Figure 4. Germline testing in the adult ALL cohort. Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL. Supplemental Figure 6. Overall survival in adults with B-ALL. Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy. Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM). Supplemental Figure 9. Expression levels of lineage-specific surface markers. Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM. Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1. Supplemental Figure 12. Clonal dynamics of ALL with MyM. Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22. Supplemental Figure 14. Clonal evolution of B-ALL2. Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy. Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses. Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab. Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab. Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.

Year:

2024

Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort. Supplemental Table 2. List of 80 genes with RNA sequencing coverage. Supplemental Table 3. Demographics of 400 adult ALL cases. Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients. Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients. Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients. Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort. Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients. Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments. Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment. Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.

Year:

2024

Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort. Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL. Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations. Supplemental Figure 4. Germline testing in the adult ALL cohort. Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL. Supplemental Figure 6. Overall survival in adults with B-ALL. Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy. Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM). Supplemental Figure 9. Expression levels of lineage-specific surface markers. Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM. Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1. Supplemental Figure 12. Clonal dynamics of ALL with MyM. Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22. Supplemental Figure 14. Clonal evolution of B-ALL2. Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy. Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses. Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab. Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab. Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.

Year:

2024

Myeloid neoplasms arise from preexisting clonal hematopoiesis (CH); however, the role of CH in the pathogenesis of acute lymphoblastic leukemia (ALL) is unknown. We found that 18% of adult ALL cases harbored TP53 , and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single-cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of these clones expanded over time to manifest as dominant clones in ALL. Single-cell RNA sequencing revealed upregulation of genes associated with cell survival and resistance to apoptosis in B-ALL with MyM, which responds better to newer immunotherapeutic approaches. These findings define ALL with MyM as a high-risk disease that can arise from antecedent CH and offer new mechanistic insights to develop better therapeutic and preventative strategies. Significance: CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years before diagnosis, and ALL with MyM is enriched with activated T cells that respond to immunotherapies such as blinatumomab. See related commentary by Iacobucci, p. 142 .

Year:

2024

Year:

2024

Year:

2023

Collaborators (26)

Marlise Luskin

Dana-Farber Cancer Institute

UNITED STATES
View details

Girish Venkataraman

Asst Professor

University of Chicago Pritzker School of Medicine

UNITED STATES
View details

Sandeep Gurbuxani

Professor

University of Chicago

UNITED STATES
View details

Rosa Lapalombella

Ohio State University

UNITED STATES
View details

Anand Ashwin Patel

Assistant Professor of Medicine

-

UNITED STATES
View details

Adam Sperling

Assistant Professor

Stanford University

UNITED STATES
View details

Mingjie Zheng

Assistant Professor

Zhejiang University

CHINA
View details

Benjamin Ebert

Dana-Farber Cancer Institute

UNITED STATES
View details

Lachelle Dawn Weeks

Dana-Farber Cancer Institute

UNITED STATES
View details

Eduardo F. Gallo

Assistant Professor

Fordham University

UNITED STATES
View details

Sofiya Milman

Associate Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Daniel Arber

Professor and Chair

University of Chicago

UNITED STATES
View details

Ulrich Steidl

Albert Einstein College of Medicine

UNITED STATES
View details

Lucy A. Godley

Northwestern Medicine

UNITED STATES
View details

Marija Kundakovic

Professor

Fordham University

UNITED STATES
View details

Deepa Rastogi

Albert Einstein College of Medicine

UNITED STATES
View details

Dianna M Milewicz

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Peng Wang

Associate professor

University of Chicago Medicine

UNITED STATES
View details

David Knowles

Assistant Professor

Columbia University

UNITED STATES
View details

Wendy Stock

Professor of Medicine

University of Chicago

UNITED STATES
View details

Srilakshmi M Raj

Assistant Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Richard Larson

Professor

University of Chicago

UNITED STATES
View details

Masako Suzuki

Assistant Professor

Texas A&M University

UNITED STATES
View details

Angela Lager

Assistant Professor

University of Chicago

UNITED STATES
View details

Tuuli Lappalainen

Professor at KTH Royal Institute of Technology

KTH Royal Institute of Technology

SWEDEN
View details

Mariko Isshiki

Project Assistant Professor

University of Tokyo

JAPAN
View details